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Background: TAVR has emerged as a less invasive option for valve replacement for high-risk and inoperable patients with severe AS. However, not 
all TAVR patients derive a mortality or quality of life (QoL) benefit. We aimed to identify patients at high-risk for a poor outcome after TAVR.
methods: We examined QoL and mortality outcomes among 463 patients randomized to TAVR from the PARTNER I trial. QoL was assessed using 
the Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100; higher=better) at baseline and 6M. A poor 6M outcome--defined as either death, 
very poor QoL (KCCQ summary score <45 [~NYHA Class 4]), or a decrease in KCCQ by ≥10 points vs. baseline--occurred in 161 patients (35%). A 
multivariable model was constructed to identify a parsimonious set of covariates that could identify patients at high-risk for poor 6M outcome.
results: The final model included a combination of clinical, echocardiographic, and health status variables. The model demonstrated good 
discrimination (c-index=0.72) and calibration with the observed data. Based on baseline characteristics alone, the model identified 95 patients 
(21%) with a ≥50% likelihood of a poor 6M outcome after TAVR. The highest risk patients (top 10%) had a >66% likelihood of a poor outcome. High-
risk patients (vs. low-risk) were more likely to have lower body weights (BMI: 24.6 vs. 29.6 kg/m2, p<0.001), worse kidney function (Cr: 1.4 vs. 1.2 
mg/dL, p=0.073), lower mean aortic valve gradients (35 vs. 49 mmHg, p=0.004), oxygen-dependent COPD (27% vs. 5%, p<0.001), worse functional 
status (6-min walk distance: 37 vs. 143 m, p<0.001), worse mental health (SF-12 mental score: 36 vs. 52, p<0.001) and worse QoL at baseline 
(KCCQ: 28 vs. 47, p<0.001). At 6M, 33% of high-risk patients were dead and an additional 25% had very poor QoL. In comparison, only 10% of low-
risk patients were dead and 7% had a very poor QoL at 6M after TAVR.
conclusion: Using a large, multicenter cohort of patients undergoing TAVR, we have established a set of covariates that can identify patients at 
high-risk for poor 6 month outcomes after TAVR. Such a model may help guide treatment choices and provide patients realistic expectations of 
outcomes based on their presenting characteristics.
